(CercleFinance.com) – Genfit is up more than 3% in Paris, benefiting from the analysis of Oddo qio maintains its ‘outperformance’ rating on the title, with a price target raised to 10.2 euros, against 6 , 3 euros previously.
The analysis office reminds that Genfit has an agreement of 480 ME with Ipsen for the elafibranor license. ‘In addition to this agreement, Ipsen takes a stake in the company with the purchase of 4 million shares for an amount of 28 ME “, specifies Oddo.
In addition, Genfit confirms the schedule for the PBC study currently in phase 3 and the results should arrive at the beginning of 2023. The objective is a commercialization at the end of 2024 / beginning of 2025.
Under these conditions, ‘the financial terms seem to us to be excellent for Genfit by allowing full refinancing of the company’, concludes the analyst.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
